Trends in Shortages of Lead Chelators From 2001 to 2022.

The study aims to describe drug shortages affecting lead chelators in the United States from 2001 through 2022. Drug shortage data were retrieved from the University of Utah Drug Information Service from January 1, 2001, through December 31, 2022. Shortages of first- and second-line lead chelators were analyzed. Drug class, formulation, administration route, shortage reason, shortage duration, generic status, single-source status, and presence of temporally overlapping shortages were examined. Total shortage months, percentages of study period on shortage, and median shortage durations were calculated. Thirteen lead chelator shortages were reported during the study period. Median duration was 7.4 months and the longest shortage (24.8 months) involved calcium disodium edetate. Calcium disodium edetate and dimercaprol had the greatest number of shortages, 4 each, and 61.5% of shortages involved parenteral medications. Median shortage duration was 14.2 months for parenteral agents and 2.2 months for non-parenteral agents. All shortages involved generic, single-source products. Supply/demand and manufacturing problems were the most common shortage reasons provided. Overlapping shortages occurred for 3.7% of the study period. Median shortage duration increased from 3 to 11 months in the second half of the study period, and 61.5% of shortages occurred in the second half of the study period. All chelators experienced multiple shortages, which became increasingly frequent and prolonged over time. Concurrent shortages occurred, potentially hampering substitution between different agents. Health care stakeholders must build supply chain resilience and develop guidelines regarding how to modify chelation therapy based on shortage conditions.

Informations de copyright

Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: [e-mail].

Déclaration de conflit d'intérêts

Disclosures. MMA, DPC, KMG, PS, and JDW declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. ERF leads the University of Utah Drug Information Service (UUDIS). The UUDIS has a contract with Vizient (a GPO) to provide drug shortage information. The total amount represents less than 5% of the UUDIS budget. No funds are paid directly to Erin Fox. Erin Fox receives partial travel support for providing continuing education on drug shortages from the Drug Information Association.